Metformin and everolimus in neuroendocrine tumours: A synergic effect?

Area of Science:

• Oncology
• Pharmacology
• Medical Research

Background:

• Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms.
• The mTOR pathway is a target for NET treatment, with everolimus being a key inhibitor.
• Metformin's potential synergistic effects with mTOR inhibitors are under investigation.

Purpose of the Study:

• To evaluate the potential synergy between metformin and everolimus in patients with advanced gastroenteropancreatic or lung neuroendocrine tumors (NET).
• To compare progression-free survival (PFS) in NET patients treated with everolimus, stratified by diabetes status and metformin use.

Main Methods:

• A retrospective cohort study of 213 advanced NET patients treated with everolimus.
• Patients were categorized into three groups: non-diabetic, diabetic without metformin, and diabetic with metformin.
• Progression-free survival (PFS) was the primary endpoint, analyzed using univariate and multivariate methods.

Main Results:

• No significant difference in median PFS was observed between the non-diabetic, diabetic with metformin, and diabetic without metformin groups.
• Metformin use was not found to be a significant factor associated with longer PFS in univariate or multivariate analyses.
• Factors such as functioning NET, fewer metastatic sites, absence of lung metastasis, and positive Octreoscan uptake were associated with longer PFS.

Conclusions:

• The study did not find evidence of synergy between everolimus and metformin in patients with neuroendocrine tumors (NET).
• Findings contrast with some existing literature, highlighting the need for further investigation.
• Ongoing prospective studies aim to clarify the potential role of this combination therapy in specific NET populations and tumor types.